Last updated: 2026-10-13 07:27:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Solid Biosciences Inc. (SLDB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $6.70, with a market capitalisation of $736.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.79 to $11.45. This page covers its latest market performance, valuation, price trends and company information.
$736.64M | |
$6.85 | |
$822.60 | |
$1.81 | |
$6.87 | |
462.50K | |
1.08M | |
-- | |
$11.45 | |
$3.79 | |
-- | |
-- |
Solid Biosciences Inc. (SLDB) last closed at $6.87 as of 2026-10-12 23:31:00, unchanged from the previous close of $6.87.
During the latest regular trading session, SLDB traded between $1.81 and $822.60, with a volume of 462.50K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Solid Biosciences Inc. (SLDB) moved from $6.85 to $6.70, representing a decline of 2.26% ($0.15).
The stock traded between $6.64 and $7.26 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.02 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.9%
SLDB is currently trading at $6.70, placing it 37.9% of the way from its 52-week low of $3.79 to its 52-week high of $11.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 121 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Solid Biosciences Inc. (SLDB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.